Education
About Us
Working with TipRanks
Follow Us
CombiGene AB (SE:LARK)
:LARK
LARK Stock Chart & Stats
kr2.35
--
Market closed
kr2.35
--
Day’s Range― - ―
52-Week Rangekr1.98 - kr2.87
Previous CloseN/A
VolumeN/A
Average Volume (3M)41.41K
Market Cap
kr46.53M
Enterprise Value-kr11.57M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta-0.08
Next Earnings
Nov 07, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield8.47%
Share Statistics
EPS (TTM)-0.62
Shares Outstanding19,801,197
10 Day Avg. Volume70,026
30 Day Avg. Volume41,406
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
LARK FAQ
What was CombiGene AB’s price range in the past 12 months?
CombiGene AB lowest stock price was kr1.98 and its highest was kr2.87 in the past 12 months.
What is CombiGene AB’s market cap?
CombiGene AB’s market cap is kr46.53M.
When is CombiGene AB’s upcoming earnings report date?
CombiGene AB’s upcoming earnings report date is Nov 07, 2025 which is 49 days ago.
How were CombiGene AB’s earnings last quarter?
CombiGene AB released its earnings results on Aug 22, 2025. The company reported -kr0.623 earnings per share for the quarter, missing the consensus estimate of N/A by -kr0.623.
Is CombiGene AB overvalued?
According to Wall Street analysts CombiGene AB’s price is currently Overvalued.
Does CombiGene AB pay dividends?
CombiGene AB pays a Notavailable dividend of kr1.93 which represents an annual dividend yield of 8.47%. See more information on CombiGene AB dividends here
What is CombiGene AB’s EPS estimate?
CombiGene AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CombiGene AB have?
CombiGene AB has 19,801,197 shares outstanding.
What happened to CombiGene AB’s price movement after its last earnings report?
CombiGene AB reported an EPS of -kr0.623 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -4.348%.
Which hedge fund is a major shareholder of CombiGene AB?
Currently, no hedge funds are holding shares in SE:LARK
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CombiGene AB
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two gene therapy candidates, including CG01, which is in preclinical studies for the treatment of epilepsy and biodistribution and toxicology studies; and CGT2 for the treatment of lipodystrophy. The company has a licensing and collaboration agreement with Lipigon Pharmaceuticals AB to develop a gene therapy treatment for partial lipodystrophy; and with Spark Therapeutics to develop adeno-associated virus (AAV) based gene therapies. CombiGene AB (publ) was founded in 1999 and is headquartered in Lidingö, Sweden.
Technical Analysis
2cureX AB
―
Stayble Therapeutics AB
―
LIDDS AB
―
ExpreS2ion Biotech Holding AB
―
Sprint Bioscience AB
―